Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

第2相 完了 NCT00821821

概要

The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.

Number of Participants That Experienced Adverse Events

87days · participants

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pain — Prasad Shirvalkar, MD, PhD
• Women's Health Initiative Strong and Healthy Study — Fred Hutchinson Cancer Center
• Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke — Shionogi
• Zambia Stroke Unit Study — Johns Hopkins University
• Tracking Post-stroke Walking Improvements From the Clinic Into the Home — Western University of Health Sciences
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University

すべての治験